文献速递冠心病血脂与心血管预防

基于2016 NICE指南筛选的CT冠状动脉造影诊断与预后获益:SCOT-HEART随机试验事后分析

Diagnostic and prognostic benefits of computed tomography coronary angiography using the 2016 National Institute for Health and Care Excellence guidance within a randomised trial.
PubMed 文献 · Heart · 2017-08-27

该研究为SCOT-HEART随机试验的事后分析,纳入4146例疑似心绞痛受试者随机接受CT冠状动脉造影(CTCA)。按2016 NICE指南分为可能心绞痛与非心绞痛表现后,CTCA在可能心绞痛组显著提高诊断确定性并降低正常冠状动脉造影率,随访3.2年致命或非致命心肌梗死从3.2%降至1.9%;非心绞痛组获益有限且侵入性造影率增加。

要点

  • NICE指南定义的可能的患者从CTCA中获得更大的诊断确定性和预后获益。
  • 可能心绞痛组CTCA使致命或非致命心肌梗死风险显著降低(HR 0.58)。
  • 非心绞痛症状患者从CTCA中获益 minimal 且侵入性造影率增加。

核心结论

  • NICE指南指导的患者选择可最大化CTCA在诊断确定性、侵入性冠状动脉造影使用及致命和非致命心肌梗死减少方面的获益。
  • 非心绞痛胸痛患者从CTCA中获益 minimal 且增加侵入性检查率。

研究设计与样本

  • SCOT-HEART试验的事后分析,4146例疑似心绞痛受试者随机接受CTCA。
  • 按2016 NICE指南将患者二分为可能心绞痛与非心绞痛表现,分析3770例合格受试者。
  • 主要诊断终点为6周时心绞痛的诊断确定性,预后终点为致命和非致命心肌梗死。

主要发现

  • 在可能心绞痛组,CTCA提高诊断确定性的相对风险为2.22(95%CI 1.91-2.60),p<0.001;非心绞痛组为1.30(1.11-1.53),p=0.002;交互作用p<0.001。
  • 可能心绞痛组CTCA未改变侵入性造影率(p=0.481),但显著降低正常冠状动脉造影率(HR 0.32,95%CI 0.19-0.52,p<0.001)。
  • 非心绞痛组侵入性造影率增加(HR 1.82,95%CI 1.13-2.92,p=0.014),正常冠状动脉造影率未降低(HR 0.78,95%CI 0.30-2.05,p=0.622)。
  • 随访3.2年,可能心绞痛组致命或非致命心肌梗死从3.2%降至1.9%(HR 0.58,95%CI 0.34-0.99,p=0.045);非心绞痛组无显著降低(HR 0.65,95%CI 0.25-1.69,p=0.379)。

关键数值与推荐

  • 2016 NICE指南用于评估疑似稳定型心绞痛,将患者分为可能心绞痛与非心绞痛表现。
  • 可能心绞痛组CTCA提高诊断确定性RR 2.22(1.91-2.60),非心绞痛组RR 1.30(1.11-1.53),交互作用p<0.001。
  • 可能心绞痛组正常冠状动脉造影率HR 0.32(0.19-0.52),非心绞痛组侵入性造影率HR 1.82(1.13-2.92)。
  • 可能心绞痛组致命或非致命心肌梗死HR 0.58(0.34-0.99),非心绞痛组HR 0.65(0.25-1.69)。

临床怎么用

  • 对疑似稳定型心绞痛患者,按2016 NICE指南筛选可能心绞痛患者行CTCA可提高诊断效率并改善预后。
  • 非心绞痛胸痛患者行CTCA获益有限且可能增加不必要的侵入性造影,应避免常规使用。

局限性

  • 本研究为SCOT-HEART试验的事后分析,结果需谨慎解释。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the diagnostic and prognostic benefits of CT coronary angiography (CTCA) using the 2016 National Institute for Health and Care Excellence (NICE) guidelines for the assessment of suspected stable angina. METHODS: Post hoc analysis of the Scottish COmputed Tomography of the HEART (SCOT-HEART) trial of 4146 participants with suspected angina randomised to CTCA. Patients were dichotomised into NICE guideline-defined possible angina and non-anginal presentations. Primary (diagnostic) endpoint was diagnostic certainty of angina at 6 weeks and prognostic endpoint comprised fatal and non-fatal myocardial infarction (MI). RESULTS: In 3770 eligible participants, CTCA increased diagnostic certainty more in those with possible angina (relative risk (RR) 2.22 (95% CI 1.91 to 2.60), p<0.001) than those with non-anginal symptoms (RR 1.30 (1.11 to 1.53), p=0.002; pinteraction <0.001). In the possible angina cohort, CTCA did not change rates of invasive angiography (p=0.481) but markedly reduced rates of normal coronary angiography (HR 0.32 (0.19 to 0.52), p<0.001). In the non-anginal cohort, rates of invasive angiography increased (HR 1.82 (1.13 to 2.92), p=0.014) without reducing rates of normal coronary angiography (HR 0.78 (0.30 to 2.05), p=0.622). At 3.2 years of follow-up, fatal or non-fatal MI was reduced in patients with possible angina (3.2% to 1.9%%; HR 0.58 (0.34 to 0.99), p=0.045) but not in those with non-anginal symptoms (HR 0.65 (0.25 to 1.69), p=0.379). CONCLUSIONS: NICE-guided patient selection maximises the benefits of CTCA on diagnostic certainty, use of invasive coronary angiography and reductions in fatal and non-fatal myocardial infarction. Patients with non-anginal chest pain derive minimal benefit from CTCA and increase the rates of invasive investigation. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT01149590;post results.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Adamson PD, Hunter A, Williams MC, et al. Diagnostic and prognostic benefits of computed tomography coronary angiography using the 2016 National Institute for Health and Care Excellence guidance within a randomised trial. Heart. 2017. PMID: 28844992. doi:10.1136/heartjnl-2017-311508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。